UMass Chan researchers studying Paxlovid dosing for children with COVID-19

Researchers at UMass Chan Medical School are teaming up with pharmaceutical giant Pfizer and the U.S. Food and Drug Administration to study the effects of the COVID-19 drug Paxlovid on patients aged 18 and under.

Related Keywords

Umass Chan ,Katherine Luzuriaga ,William Durbin ,Pfizer ,Drug Administration ,Umass Center ,Umass Chan Medical School ,Umass Memorial Health Care ,Chan Medical School ,Memorial Health Care ,Translational Science ,